FDA Draft guidance on Good ANDA Submission Practices [Regulatives / Guidelines]

posted by BRB  – Canada, 2018-01-03 22:42 (2392 d 17:42 ago) – Posting: # 18137
Views: 1,672

Hi all,

The FDA just posted a draft guidance on Good ANDA submission practices:

https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM591134.pdf


I found the section on deviations from product-specific guidances to be rather interesting such as:

A detailed justification for and data (such as their inclusion/exclusion criteria or demographic information) to support why their use of a particular study population does not affect their BE determination.

So for imatinib BE studies, which have been done in healthy subjects, but the guidance recommends to use patients, a detailed justification now needs to be provided?

BRB

Complete thread:

UA Flag
Activity
 Admin contact
23,119 posts in 4,859 threads, 1,647 registered users;
41 visitors (1 registered, 40 guests [including 8 identified bots]).
Forum time: 17:25 CEST (Europe/Vienna)

You can’t really say “similar” if it’s the same again you want.
“Similar” means something different.    Anthony Burgess

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5